Validated gene expression biomarker analysis for biopsy-based clinical trials in ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 5, 2014, Pages 477-485

  Boland, B S ^a,b   Boyle, D L ^a,b   Sandborn, W J ^a,b   Firestein, G S ^a,b   Levesque, B G ^a,b   Hillman, J ^b   Zhang, B ^a   Proudfoot, J ^b   Eckmann, L ^a,b   Ernst, P B ^a,b,c   Rivera Nieves, J ^a,b   Pola, S ^a   Copur Dahi, N ^a   Chang, J T ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; COLON; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; RNA, MESSENGER;

EID: 84905869614     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12862     Document Type: Article

References (30)

1. Xavier RJ, Podolsky DK,. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-34.
2. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ,. Ulcerative colitis. Lancet 2012; 380: 1606-19.
3. Sandborn WJ,. The future of inflammatory bowel disease therapy: where do we go from here? Dig Dis 2012; 30 (Suppl. 3): 140-4.
4. Colombel JF, Rutgeerts P, Reinisch W, et al,. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterol 2011; 141: 1194-201.
5. Akazawa A, Sakaida I, Higaki S, Kubo Y, Uchida K, Okita K,. Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase. J Gastroenterol 2002; 37: 345-53.
6. Leon AJ, Gomez E, Garrote JA, et al,. High levels of proinflammatory cytokines, but not markers of tissue injury, in unaffected intestinal areas from patients with IBD. Mediators Inflamm 2009; 2009: 580450.
7. Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N,. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. The American journal of gastroenterology 2002; 97: 2820-8.
8. Raddatz D, Bockemuhl M, Ramadori G,. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 2005; 17: 547-57.
9. Matsuda R, Koide T, Tokoro C, et al,. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naive ulcerative colitis during active and quiescent disease. Inflamm Bowel Dis 2009; 15: 328-34.
10. Arijs I, De Hertogh G, Machiels K, et al,. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. The American journal of gastroenterology 2011; 106: 748-61.
11. Roman J, Planell N, Lozano JJ, et al,. Evaluation of responsive gene expression as a sensitive and specific biomarker in patients with ulcerative colitis. Inflamm Bowel Dis 2013; 19: 221-9.
12. Noble CL, Abbas AR, Cornelius J, et al,. Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut 2008; 57: 1398-405.
13. Boyle DL, Rosengren S, Bugbee W, Kavanaugh A, Firestein GS,. Quantitative biomarker analysis of synovial gene expression by real-time PCR. Arthritis research & therapy 2003; 5: R352-60.
14. Schroeder KW, Tremaine WJ, Ilstrup DM,. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9.
15. Reimund JM, Wittersheim C, Dumont S, et al,. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996; 16: 144-50.
16. te Velde AA, de Kort F, Sterrenburg E, et al,. Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 325-30.
17. Noguchi A, Watanabe K, Narumi S, et al,. The production of interferon-gamma-inducible protein 10 by granulocytes and monocytes is associated with ulcerative colitis disease activity. J Gastroenterol 2007; 42: 947-56.
18. Carlsen HS, Baekkevold ES, Johansen FE, Haraldsen G, Brandtzaeg P,. B cell attracting chemokine 1 (CXCL13) and its receptor CXCR5 are expressed in normal and aberrant gut associated lymphoid tissue. Gut 2002; 51: 364-71.
19. Louis E, Ribbens C, Godon A, et al,. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000; 120: 241-6.
20. Roth J, Goebeler M, Sorg C,. S100A8 and S100A9 in inflammatory diseases. Lancet 2001; 357: 1041.
21. Kenward MG, Roger JH,. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 1997; 53: 983-97.
22. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2013. Available at: http://www.R-project.org.
23. Bates D, Maechler M, Bolker B, Walker S,. lme4: Linear mixed-effects models using Eigen and S4. R package version 1.0-4. http://CRNA.R-project.org/ package=lme4; 2013.
24. Halekoh U, Hojsgaard S,. pbkrtest: Parametric bootstrap and Kenward Roger based methods for mixed model comparison. R package version 0.3-7. http://CRAN.R-project.org/package=pbkrtest; 2013.
25. Gomes P, du Boulay C, Smith CL, Holdstock G,. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27: 92-5.
26. Feagan BG, Sandborn WJ, D'Haens G, et al,. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013; 145: 149-57 e2.
27. U.S. Department of Health and Human Services FDA, Center for Drug Evaluation and Research. Guidance for Industry: Bioanalytical Method Validation. September 2013. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM368107.pdf. Accessed 5/22/14.
28. Olsen T, Goll R, Cui G, Christiansen I, Florholmen J,. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine 2009; 46: 222-7.
29. Buch MH, Boyle DL, Rosengren S, et al,. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009; 68: 1220-7.
30. Kavanaugh A, Rosengren S, Lee SJ, et al,. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 2008; 67: 402-8.